Experimental drug tazemetostat offered to patients with rare, aggressive tumors
NCT ID NCT03874455
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a formal clinical trial. The goal is to offer a potential option when no standard therapies remain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat
- What this could lead to
- If it works, this could provide a treatment option for people with rare, aggressive tumors who have run out of standard therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are limited and may not prove effectiveness. Tazemetostat may cause side effects and not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a targeted pill stall advanced sarcomas?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?